Investor Relations
|
MNTA - (NASDAQ)
$13.83
- 0.14
|
May 18, 2012 4:00 PM ET |
Momenta Pharmaceuticals is a biotechnology company based in Cambridge, MA focused on the development of complex generics, follow-on biologics and novel drugs. In July 2010, the Company's lead product, enoxaparin sodium injection, (developed with collaboration partner Sandoz) was approved as the first generic version of Lovenox®. The Company's development pipeline includes a generic version of Copaxone, also partnered with Sandoz, follow-on biologic candidates, M118, a rationally designed low molecular weight heparin with improved therapeutic potential, and M402, a heparin-based oncology candidate in preclinical development.
View Annual Report and Proxy Material
Recent Releases
May 11, 2012
Momenta to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
May 3, 2012
Momenta Pharmaceuticals Reports First Quarter 2012 Financial Results
View all releases »
